These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 36472873)

  • 1. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.
    Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC
    JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
    Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
    JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).
    Yip TC; Lui GC; Lai MS; Wong VW; Tse YK; Ma BH; Hui E; Leung MKW; Chan HL; Hui DS; Wong GL
    Clin Infect Dis; 2023 Feb; 76(3):e26-e33. PubMed ID: 36031408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.
    Han J; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Chang E; Kim SH
    Medicine (Baltimore); 2023 Sep; 102(39):e35094. PubMed ID: 37773854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
    Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
    Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
    Chu WM; Wan EYF; Ting Wong ZC; Tam AR; Kei Wong IC; Yin Chan EW; Ngai Hung IF
    EClinicalMedicine; 2024 Jun; 72():102620. PubMed ID: 38737003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study.
    Wan EYF; Yan VKC; Wong ZCT; Chui CSL; Lai FTT; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
    EClinicalMedicine; 2023 Oct; 64():102225. PubMed ID: 37753272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
    Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y
    JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 20. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
    Jang YR; Oh Y; Kim JY
    J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.